|
Tuesday 26th April 2016 |
Text too small? |
SeaDragon missed its annual earnings guidance as a downturn in sales pushed down prices of Omega-2 oil and says the final cost of its Omega-3 refinery will be more than previously expected.
Earnings before interest, tax, depreciation and amortisation in the 12 months ended March 31 were "lower than previously indicated to the market," the Nelson-based fish oil refiner said in a statement. SeaDragon, which had previously forecast annual earnings of $144,000, will publish its audited results next month.
"The Omega-2 market has proved to be challenging in the last few months of the financial year, with SeaDragon experiencing an extension in the sales cycle due to what we believe is a short-term softening in demand which has resulted in downward pressure on prices," the company said. "As a result, Omega-2 inventory levels are higher than usual at year end, resulting in reduced cash reserves."
At the same time, SeaDragon said it will finalise the cost of its Omega-3 refinery when it announces its annual earnings. The company increased the likely cost to $10.6 million from a previous estimate of $9.15 million to $9.55 million, subject to negotiation with suppliers and the capitalisation some expense items.
The ballooning cost of SeaDragon's refinery prompted the company to raise $10 million after the project was delayed and went over budget. That capital raise introduced NZX-listed health products firm Comvita as a cornerstone investor in SeaDragon.
The company said it's still searching for a new chief executive after Ross Keeley's departure last year, and interim boss Rich Alderton will continue in that role.
The shares were unchanged at 1.4 cents, the same level they started the year at.
BusinessDesk.co.nz
No comments yet
IKE - FY26 Financial Results
Chorus submits 2025 fibre regulatory report
SPG - FY26 Annual Results
PYS - PaySauce FY26 Full Year Result and Annual Report
IFT - Infratil Full Year Results for the year ended 31 March 2026
May 27th Morning Report
RYM - FY26 marks significant year of progress
FPH reports strong revenue and profit growth for FY26
IFT - Infratil Full Year Results for the year ended 31 March 2026
PEB - Advancing Medicare Coverage Goals; Cost Contained